Although the evidence is limited, it also seems that its inactivation is a marker of aggressive disease in both primary and metastatic sites, since progression to a less differentiated tumour has been noted in mTOR negative primary tumours as well as in metastatic disease, indicating a possible change over time [32,178]. This evidence concerns the gene MTOR and neoplasm.